STOCK TITAN

Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference, scheduled for September 9, 2021, at 12:30 p.m. ET. Key executives, Kate Haviland and Fouad Namouni, will engage in a fireside chat during the event. A live webcast will be available on their website, with a replay accessible for 30 days post-presentation. Blueprint Medicines is committed to developing precision therapies for cancer and hematologic disorders, continuously advancing its pipeline since its foundation in 2011.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Sept. 2, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research & Development, will participate virtually in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET.

A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference-301366780.html

SOURCE Blueprint Medicines Corporation

FAQ

When is Blueprint Medicines participating in the Morgan Stanley Global Healthcare Conference?

Blueprint Medicines will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 12:30 p.m. ET.

Who are the key executives participating in the fireside chat?

Kate Haviland, Chief Operating Officer, and Fouad Namouni, President of Research & Development, will participate in the fireside chat.

Where can I watch the Blueprint Medicines conference presentation?

The presentation will be available via a live webcast on Blueprint Medicines' website in the Investors & Media section.

How long will the replay of the webcast be available?

A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

What does Blueprint Medicines focus on?

Blueprint Medicines focuses on inventing precision therapies for cancer and hematologic disorders.

Blueprint Medicines Corporation

NASDAQ:BPMC

BPMC Rankings

BPMC Latest News

BPMC Stock Data

5.66B
62.62M
0.92%
106.33%
5.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE